Neuland Laboratories Limited (NEULANDLAB) - Total Liabilities
Based on the latest financial reports, Neuland Laboratories Limited (NEULANDLAB) has total liabilities worth Rs9.14 Billion INR (≈ $98.83 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Neuland Laboratories Limited cash conversion from operations to assess how effectively this company generates cash.
Neuland Laboratories Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Neuland Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Neuland Laboratories Limited to evaluate the company's liquid asset resilience ratio.
Neuland Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Neuland Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WHA Corporation Public Company Limited
BK:WHA
|
Thailand | ฿60.80 Billion |
|
The Navigator Company SA
LS:NVG
|
Portugal | €1.91 Billion |
|
Interparfums SA
PA:ITP
|
France | €311.70 Million |
|
Simplo Technology Co Ltd
TWO:6121
|
Taiwan | NT$37.50 Billion |
|
Anhui Jiangnan Chemical Industry Co Ltd
SHE:002226
|
China | CN¥8.02 Billion |
|
Smartfit Escola de Ginástica e Dança S.A
SA:SMFT3
|
Brazil | R$13.37 Billion |
|
First National Financial Corp
TO:FN
|
Canada | CA$53.65 Billion |
|
Zhuzhou Huarui Precision Cutting Tools Co Ltd
SHG:688059
|
China | CN¥1.32 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Neuland Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Neuland Laboratories Limited market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuland Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuland Laboratories Limited (2006–2025)
The table below shows the annual total liabilities of Neuland Laboratories Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs6.55 Billion ≈ $70.84 Million |
+19.14% |
| 2024-03-31 | Rs5.50 Billion ≈ $59.46 Million |
-6.11% |
| 2023-03-31 | Rs5.86 Billion ≈ $63.34 Million |
+7.86% |
| 2022-03-31 | Rs5.43 Billion ≈ $58.72 Million |
+0.87% |
| 2021-03-31 | Rs5.38 Billion ≈ $58.22 Million |
+3.32% |
| 2020-03-31 | Rs5.21 Billion ≈ $56.35 Million |
+20.87% |
| 2019-03-31 | Rs4.31 Billion ≈ $46.62 Million |
-16.03% |
| 2018-03-31 | Rs5.13 Billion ≈ $55.52 Million |
+51.00% |
| 2017-03-31 | Rs3.40 Billion ≈ $36.77 Million |
+0.76% |
| 2016-03-31 | Rs3.37 Billion ≈ $36.49 Million |
-3.57% |
| 2015-03-31 | Rs3.50 Billion ≈ $37.84 Million |
-2.60% |
| 2014-03-31 | Rs3.59 Billion ≈ $38.85 Million |
+10.59% |
| 2013-03-31 | Rs3.25 Billion ≈ $35.13 Million |
-7.03% |
| 2012-03-31 | Rs3.49 Billion ≈ $37.79 Million |
-0.74% |
| 2011-03-31 | Rs3.52 Billion ≈ $38.07 Million |
+6.93% |
| 2010-03-31 | Rs3.29 Billion ≈ $35.61 Million |
+10.57% |
| 2009-03-31 | Rs2.98 Billion ≈ $32.20 Million |
+33.75% |
| 2008-03-31 | Rs2.23 Billion ≈ $24.08 Million |
+59.28% |
| 2007-03-31 | Rs1.40 Billion ≈ $15.12 Million |
+47.24% |
| 2006-03-31 | Rs949.26 Million ≈ $10.27 Million |
-- |
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.